Asymmetric hydrogenation

In 1956 a heterogeneous catalyst made of palladium deposited on silk was shown to effect asymmetric hydrogenation. Later, in 1968, the groups of William Knowles and Leopold Horner independently published the examples of asymmetric hydrogenation using a homogeneous catalysts. While exhibiting only modest enantiomeric excesses, these early reactions demonstrated feasibility. By 1972, enantiomeric excess of 90% was achieved, and the first industrial synthesis of the Parkinson's drug L-DOPA commenced using this technology. Robert H. Crabtree demonstrated the ability for Iridium compounds to catalyse asymmetric hydrogenation reactions in 1979 with the invention of Crabtree's catalyst. In the early 1990's, the introduction of P,N ligands by several groups independently then further expanded the scope of the C2-symmetric ligands, although they are not fundamentally superior to chiral ligands lacking rotational symmetry. Today, asymmetric hydrogenation is a routine methodology in laboratory and industrial scale organic chemistry. The importance of asymmetric hydrogenation was recognized by the 2001 Nobel Prize in Chemistry awarded to William Standish Knowles and Ryōji Noyori. == Mechanism ==

Asymmetric hydrogenations operate by conventional mechanisms invoked for other hydrogenations. This includes inner sphere mechanisms, outer sphere mechanisms and the σ-bond metathesis mechanisms. The type of mechanism employed by a catalyst is largely dependent on the ligands used in a system, which in turn leads to certain catalyst-substrate affinities. Inner sphere mechanisms The so-called inner sphere mechanism entails coordination of the alkene to the metal center. Other characteristics of this mechanism include a tendency for a homolytic splitting of dihydrogen when more electron-rich, low-valent metals are present while electron-poor, high valent metals normally exhibit a heterolytic cleavage of dihydrogen assisted by a base. The diagram below depicts purposed mechanisms for catalytic hydrogenation with rhodium complexes which are inner sphere mechanisms. In the unsaturated mechanism, the chiral product formed will have the opposite mode compared to the catalyst used. While the thermodynamically favoured complex between the catalyst and the substrate is unable to undergo hydrogenation, the unstable, unfavoured complex undergoes hydrogenation rapidly. The dihydride mechanism on the other hand sees the complex initially hydrogenated to the dihydride form. This subsequently allows for the coordination of the double bond on the non-hindered side. Through insertion and reductive elimination, the product's chirality matches that of the ligand. The preference for producing one enantiomer instead of another in these reactions is often explained in terms of steric interactions between the ligand and the prochiral substrate. Consideration of these interactions has led to the development of quadrant diagrams where "blocked" areas are denoted with a shaded box, while "open" areas are left unfilled. In the modeled reaction, large groups on an incoming olefin will tend to orient to fill the open areas of the diagram, while smaller groups will be directed to the blocked areas and hydrogen delivery will then occur to the back face of the olefin, fixing the stereochemistry. Note that only part of the chiral phosphine ligand is shown for the sake of clarity. Outer sphere mechanisms Some catalysts operate by "outer sphere mechanisms" such that the substrate never bonds directly to the metal but rather interacts with its ligands, which is often a metal hydride and a protic hydrogen on a ligand. As such, in most cases dihydrogen is split heterolytically, with the metal acting as a Lewis acid and either an external or internal base "deprotonating" the hydride. In the hydrogenation of C=O containing substrates, the mechanism was long assumed to operate by a six membered pericyclic transition state/intermediate whereby the hydrido ruthenium hydride center (HRu-NH) interacts with the carbonyl substrate R2C=O. More recent DFT and experimental studies have shown that this model is largely incorrect. Instead, the amine backbone interacts strongly with the base activator, which often is used in large excess. However in both cases, the substrate does not bond directly with the metal centre, thus making it a great example of an outer sphere mechanism. == Metals ==

Practical AH employ platinum metal-based catalysts. Unfunctionalized olefins are the archetypal case, --> Base metals Iron is a popular research target for many catalytic processes, owing largely to its low cost and low toxicity relative to other transition metals. Asymmetric hydrogenation methods using iron have been realized, although in terms of rates and selectivity, they are inferior to catalysts based on precious metals. In some cases, structurally ill-defined nanoparticles have proven to be the active species in situ and the modest selectivity observed may result from their uncontrolled geometries. == Ligand classes ==

Phosphine ligands Chiral phosphine ligands, especially C2-symmetric ligands, are the source of chirality in most asymmetric hydrogenation catalysts. Of these the BINAP ligand is well-known, as a result of its Nobel Prize-winning application in the Noyori asymmetric hydrogenation. Chiral phosphine ligands can be generally classified as mono- or bidentate. They can be further classified according to the location of the stereogenic centre – phosphorus vs the organic substituents. Ligands with a C2 symmetry element have been particularly popular, in part because the presence of such an element reduces the possible binding conformations of a substrate to a metal-ligand complex dramatically (often resulting in exceptional enantioselectivity). Monodentate phosphines Monophosphine-type ligands were among the first to appear in asymmetric hydrogenation, e.g., the ligand CAMP. Continued research into these types of ligands has explored both P-alkyl and P-heteroatom bonded ligands, with P-heteroatom ligands like the phosphites and phosphoramidites generally achieving more impressive results. Structural classes of ligands that have been successful include those based on the binapthyl structure of MonoPHOS or the spiro ring system of SiPHOS. Notably, these monodentate ligands can be used in combination with each other to achieve a synergistic improvement in enantioselectivity; something that is not possible with the diphosphine ligands.) and what is likely the best known chiral ligand (BINAP). However, these symmetric ligands were soon superseded by monooxazoline ligands whose lack of C2 symmetry has in no way limits their efficacy in asymmetric catalysis. Such ligands generally consist of an achiral nitrogen-containing heterocycle that is functionalized with a pendant phosphorus-containing arm, although both the exact nature of the heterocycle and the chemical environment phosphorus center has varied widely. No single structure has emerged as consistently effective with a broad range of substrates, although certain privileged structures (like the phosphine-oxazoline or PHOX architecture) have been established. Moreover, within a narrowly defined substrate class the performance of metallic complexes with chiral P,N ligands can closely approach perfect conversion and selectivity in systems otherwise very difficult to target. Certain complexes derived from chelating P-O ligands have shown promising results in the hydrogenation of α,β-unsaturated ketones and esters. NHC ligands for asymmetric hydrogenation|alt=Chemical diagram Simple N-heterocyclic carbene (NHC)-based ligands have proven impractical for asymmetrical hydrogenation. Some C,N ligands combine an NHC with a chiral oxazoline to give a chelating ligand. NHC-based ligands of the first type have been generated as large libraries from the reaction of smaller libraries of individual NHCs and oxazolines. The same system has been applied to the synthesis of a number of aldol, vicinal dimethyl and deoxypolyketide motifs, and to the deoxypolyketides themselves. C2-symmetric NHCs have shown themselves to be highly useful ligands for the asymmetric hydrogenation. == Acyclic substrates ==

Substrates can be classified according to their polarity. Nonpolar substrates are dominated by alkenes. Polar substrates include ketones, enamines ketimines. Nonpolar substrates Alkenes that are particularly amenable to asymmetric hydrogenation often feature a polar functional group adjacent to the site to be hydrogenated. In the absence of this functional group, catalysis often results in low ee's. For some unfunctionalized olefins, iridium with P,N-based ligands) have proven effective, however. Alkene substrates are often classified according to their substituents, e.g., 1,1-disubstituted, 1,2-diaryl trisubstituted, 1,1,2-trialkyl and tetrasubstituted olefins. and even within these classes variations may exist that make different solutions optimal. Conversely to the case of olefins, asymmetric hydrogenation of enamines has favoured diphosphine-type ligands; excellent results have been achieved with both iridium- and rhodium-based systems. However, even the best systems often suffer from low ee's and a lack of generality. Certain pyrrolidine-derived enamines of aromatic ketones are amenable to asymmetrically hydrogenation with cationic rhodium(I) phosphonite systems, and I2 and acetic acid system with ee values usually above 90% and potentially as high as 99.9%. A similar system using iridium(I) and a very closely related phosphoramidite ligand is effective for the asymmetric hydrogenation of pyrrolidine-type enamines where the double bond was inside the ring: in other words, of dihydropyrroles. In both cases, the enantioselectivity dropped substantially when the ring size was increased from five to six. Imines and ketones Ketones and imines are related functional groups, and effective technologies for the asymmetric hydrogenation of each are also closely related. Early examples are Noyori's ruthenium-chiral diphosphine-diamine system. For carbonyl and imine substrates, end-on, η1 coordination can compete with η2 mode. For η1-bound substrates, the hydrogen-accepting carbon is removed from the catalyst and resists hydrogenation. Iridium/P,N ligand-based systems have been effective for some ketones and imines. For example, a consistent system for benzylic aryl imines uses the P,N ligand SIPHOX in conjunction with iridium(I) in a cationic complex to achieve asymmetric hydrogenation with ee >90%. An efficient catalyst for ketones, (turnover number (TON) up to 4,550,000 and ee up to 99.9%) is an iridium(I) system with a closely related tridentate ligand. The BINAP/diamine-Ru catalyst is effective for the asymmetric reduction of both functionalized and simple ketones, and BINAP/diamine-Ru catalyst can catalyze aromatic, heteroaromatic, and olefinic ketones enantioselectively. Better stereoselectivity is achieved when one substituent is larger than the other (see Flippin-Lodge angle). == Aromatic substrates ==

The asymmetric hydrogenation of aromatic (especially heteroaromatic), substrates is a very active field of ongoing research. Catalysts in this field must contend with a number of complicating factors, including the tendency of highly stable aromatic compounds to resist hydrogenation, the potential coordinating (and therefore catalyst-poisoning) abilities of both substrate and product, and the great diversity in substitution patterns that may be present on any one aromatic ring. Of these substrates the most consistent success has been seen with nitrogen-containing heterocycles, where the aromatic ring is often activated either by protonation or by further functionalization of the nitrogen (generally with an electron-withdrawing protecting group). Such strategies are less applicable to oxygen- and sulfur-containing heterocycles, since they are both less basic and less nucleophilic; this additional difficulty may help to explain why few effective methods exist for their asymmetric hydrogenation. Quinolines, isoquinolines and quinoxalines Two systems exist for the asymmetric hydrogenation of 2-substituted quinolines with isolated yields generally greater than 80% and ee values generally greater than 90%. The first is an iridium(I)/chiral phosphine/I2 system, first reported by Zhou et al.. While the first chiral phosphine used in this system was MeOBiPhep, newer iterations have focused on improving the performance of this ligand. To this end, systems use phosphines (or related ligands) with improved air stability, recyclability, lower catalyst loading and the potential role of achiral phosphine additives. As of October 2012 no mechanism appears to have been proposed, although both the necessity of I2 or a halogen surrogate and the possible role of the heteroaromatic N in assisting reactivity have been documented. Much of the asymmetric hydrogenation chemistry of quinoxalines is closely related to that of the structurally similar quinolines. Effective (and efficient) results can be obtained with an Ir(I)/phophinite/I2 system and a Hantzsh ester-based organocatalytic system, both of which are similar to the systems discussed earlier with regards to quinolines. Pyridines Pyridines are highly variable substrates for asymmetric reduction (even compared to other heteroaromatics), in that five carbon centers are available for differential substitution on the initial ring. As of October 2012 no method seems to exist that can control all five, although at least one reasonably general method exists. The most-general method of asymmetric pyridine hydrogenation is actually a heterogeneous method, where asymmetry is generated from a chiral oxazolidinone bound to the C2 position of the pyridine. Hydrogenating such functionalized pyridines over a number of different heterogeneous metal catalysts gave the corresponding piperidine with the substituents at C3, C4, and C5 positions in an all-cis geometry, in high yield and excellent enantioselectivity. The oxazolidinone auxiliary is also conveniently cleaved under acidic conditions as a second step. Methods designed specifically for 2-substituted pyridine hydrogenation can involve asymmetric systems developed for related substrates like 2-substituted quinolines and quinoxalines. For example, an iridium(I)\chiral phosphine\I2 system is effective in the asymmetric hydrogenation of activated (alkylated) 2-pyridiniums or certain cyclohexanone-fused pyridines. Similarly, chiral Brønsted acid catalysis with a Hantzsh ester as a hydride source is effective for some 2-alkyl pyridines with additional activating substitution. Indoles and pyrroles The asymmetric hydrogenation of indoles has been established with N-Boc protection. A Pd(TFA)2/H8-BINAP system achieves the enantioselective cis-hydrogenation of 2,3- and 2-substituted indoles. Akin to the behavior of indoles, pyrroles can be converted to pyrrolidines by asymmetric hydrogenation. Oxygen- and sulfur-containing heterocycles The asymmetric hydrogenation of furans and benzofurans is challenging. Asymmetric hydrogenation of thiophenes and benzothiophenes has been catalyzed by some ruthenium(II) complexes of N-heterocyclic carbenes (NHC). This system appears to possess superb selectivity (ee > 90%) and perfect diastereoselectivity (all cis) if the substrate has a fused (or directly bound) phenyl ring but yields only racemic product in all other tested cases. == Heterogeneous catalysis ==

No heterogeneous catalyst has been commercialized for asymmetric hydrogenation. The first asymmetric hydrogenation focused on palladium deposited on a silk support. Cinchona alkaloids have been used as chiral modifiers for enantioselectivity hydrogenation. , one of the cinchona alkaloids An alternative technique and one that allows more control over the structural and electronic properties of active catalytic sites is the immobilization of catalysts that have been developed for homogeneous catalysis on a heterogeneous support. Covalent bonding of the catalyst to a polymer or other solid support is perhaps most common, although immobilization of the catalyst may also be achieved by adsorption onto a surface, ion exchange, or even physical encapsulation. One drawback of this approach is the potential for the proximity of the support to change the behaviour of the catalyst, lowering the enantioselectivity of the reaction. To avoid this, the catalyst is often bound to the support by a long linker though cases are known where the proximity of the support can actually enhance the performance of the catalyst. One of these involved ruthenium-based catalysts. As little as 0.005 mol% of such catalysts proved sufficient to achieve the asymmetric hydrogenation of aryl ketones, although the usual conditions featured 0.1 mol % of catalyst and resulted in an enantiomeric excess of 90.6–99.2%. == Industrial applications ==

Asymmetric hydrogenations are used in the production of several drugs, such as the antibacterial levofloxacin, the antibiotic carbapenem, and the antipsychotic agent BMS181100. Knowles' research into asymmetric hydrogenation and its application to the production scale synthesis of L-Dopa Asymmetric hydrogenation has replaced kinetic resolution based methods has resulted in substantial improvements in the process's efficiency. can be seen in a number of specific cases where the For example, Roche's Catalysis Group was able to achieve the synthesis of (S,S)-Ro 67-8867 in 53% overall yield, a dramatic increase above the 3.5% that was achieved in the resolution based synthesis. Roche's synthesis of mibefradil was likewise improved by replacing resolution with asymmetric hydrogenation, reducing the step count by three and increasing the yield of a key intermediate to 80% from the original 70%. Noyori-inspired hydrogenation catalysts have been applied to the commercial synthesis of number of fine chemicals. (R)-1,2-Propandiol, precursor to the antibacterial levofloxacin, can be efficiently synthesized from hydroxyacetone using Noyori asymmetric hydrogenation: An antibiotic carbapenem is also prepared using Noyori asymmetric hydrogenation via (2S,3R)-methyl 2-(benzamidomethyl)-3-hydroxybutanoate, which is synthesized from racemic methyl 2-(benzamidomethyl)-3-oxobutanoate by dynamic kinetic resolution. An antipsychotic agent BMS-181100 is synthesized using BINAP/diamine-Ru catalyst. == References ==